Literature DB >> 17119885

[Advances in radio-oncology. From precision radiotherapy with photons to ion therapy with protons and carbon ions].

S E Combs1, D Schulz-Ertner, K K Herfarth, R Krempien, J Debus.   

Abstract

Modern techniques in radiation oncology, such as fractionated stereotactic radiotherapy (FSRT), stereotactic radiosurgery (SRS) or intensity modulated radiotherapy (IMRT) allow the application of high local doses to defined treatment volumes, while normal structures in close vicinity can be spared; high local control rates can be achieved, while treatment-related toxicity can be minimized. Innovative Hi-Art tomotherapy systems offer an alternative, combining a 6 MV photon accelerator with a CT scanner. Ion beams, such as protons and carbon ions, have been shown to be beneficial for distinct tumor entities. Both offer a characteristic physical dose distribution with an inverse dose profile contributing to beneficial dose conformality. Carbon ions also offer the advantage of increased relative biological effectiveness. For certain tumor types, a significant increase in local control and survival rates could be obtained with carbon ions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119885     DOI: 10.1007/s00104-006-1268-2

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  13 in total

Review 1.  Tolerance of normal tissue to therapeutic irradiation.

Authors:  B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-05-15       Impact factor: 7.038

2.  Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques.

Authors:  Daniela Schulz-Ertner; Anna Nikoghosyan; Bernd Didinger; Marc Münter; Oliver Jäkel; Christian P Karger; Juergen Debus
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

3.  Fractionated stereotactic conformal radiation therapy of brain stem gliomas: outcome and prognostic factors.

Authors:  D Schulz-Ertner; J Debus; F Lohr; C Frank; A Höss; M Wannenmacher
Journal:  Radiother Oncol       Date:  2000-11       Impact factor: 6.280

4.  Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial.

Authors:  K K Herfarth; J Debus; F Lohr; M L Bahner; B Rhein; P Fritz; A Höss; W Schlegel; M F Wannenmacher
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

5.  Carbon ion radiation therapy for chordomas and low grade chondrosarcomas--current status of the clinical trials at GSI.

Authors:  Daniela Schulz-Ertner; Anna Nikoghosyan; Bernd Didinger; Jürgen Debus
Journal:  Radiother Oncol       Date:  2004-12       Impact factor: 6.280

6.  Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.

Authors:  Stefanie Milker-Zabel; Angelika Zabel-du Bois; Marcus Henze; Peter Huber; Daniela Schulz-Ertner; Angelika Hoess; Uwe Haberkorn; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-02-20       Impact factor: 7.038

7.  Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery.

Authors:  Stephanie E Combs; Daniela Schulz-Ertner; Christoph Thilmann; Lutz Edler; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2004-09       Impact factor: 3.621

8.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

9.  Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience.

Authors:  Andrea Pirzkall; Jürgen Debus; Peter Haering; Bernhard Rhein; Karl Heinz Grosser; Angelika Höss; M Wannenmacher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

10.  Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Authors:  R Krempien; M W Muenter; P E Huber; S Nill; H Friess; C Timke; B Didinger; P Buechler; S Heeger; K K Herfarth; A Abdollahi; M W Buchler; J Debus
Journal:  BMC Cancer       Date:  2005-10-11       Impact factor: 4.430

View more
  6 in total

Review 1.  Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.

Authors:  Stephanie E Combs
Journal:  Langenbecks Arch Surg       Date:  2015-07-03       Impact factor: 3.445

Review 2.  Does Proton Therapy Have a Future in CNS Tumors?

Authors:  Stephanie E Combs
Journal:  Curr Treat Options Neurol       Date:  2017-03       Impact factor: 3.598

3.  Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.

Authors:  Daniel Habermehl; Katrin Henkner; Swantje Ecker; Oliver Jäkel; Jürgen Debus; Stephanie E Combs
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

4.  Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013".

Authors:  Stephanie E Combs; Jürgen Debus; Günter Feick; Boris Hadaschik; Markus Hohenfellner; Roland Schüle; Jens-Peter Zacharias; Malte Schwardt
Journal:  Radiat Oncol       Date:  2014-11-04       Impact factor: 3.481

Review 5.  Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer?

Authors:  Kilian C Schiller; Gregor Habl; Stephanie E Combs
Journal:  Front Oncol       Date:  2016-01-28       Impact factor: 6.244

6.  Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy.

Authors:  Falk Stade; Jan-Oliver Dittmar; Oliver Jäkel; Clemens Kratochwil; Uwe Haberkorn; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2018-04-02       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.